You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CLL1

Showing 1 - 25 of 1,162
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

AML, Adult Trial in Hangzhou (CLL1 CAR-NK cell injection)

Recruiting
  • AML, Adult
  • CLL1 CAR-NK cell injection
  • Hangzhou, Zhejiang, China
    Clinical research ethics committee of the first affiliated hospi
Aug 30, 2023

Acute Myeloid Leukemia Trial in Kunming (CLL1 and CD38 dual-target CAR-T injection)

Recruiting
  • Acute Myeloid Leukemia
  • CLL1 and CD38 dual-target CAR-T injection
  • Kunming, Yunnan, China
    920th Hospital of Joint LogisticsSupport Force of People's Liber
Oct 26, 2023

Acute Myeloid Leukemia Trial in Fuzhou (CLL1/+CD33 CAR-T)

Not yet recruiting
  • Acute Myeloid Leukemia
  • CLL1/+CD33 CAR-T
  • Fuzhou, Fujian, China
    Fujian Provincial Children's Hospital
Jul 10, 2023

AML Trial in Hangzhou (CLL1 CAR-T)

Not yet recruiting
  • AML
  • CLL1 CAR-T
  • Hangzhou, China
    The First Affiliated Hospital, Zhejiang University
Jul 17, 2022

AML Trial in Hangzhou (CLL1+CD33 CAR-T)

Not yet recruiting
  • AML
  • CLL1+CD33 CAR-T
  • Hangzhou, China
    Mingming Zhang Zhang
Jul 19, 2022

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • (no location specified)
Nov 9, 2023

AML Trial in Hangzhou (CLL1 CAR T-cells)

Recruiting
  • AML
  • CLL1 CAR T-cells
  • Hangzhou, Zhejiang, China
  • +1 more
Feb 13, 2022

Acute Myeloid Leukemia Trial in Kunming (Anti-CLL1 CART cells)

Recruiting
  • Acute Myeloid Leukemia
  • Anti-CLL1 CART cells
  • Kunming, Yunnan, China
    No.212 Daguan Road, Xishan District
Nov 23, 2022

Acute Myeloid Leukemia Trial in Wuxi (Anti-CD33/CLL1 CAR-NK Cells)

Recruiting
  • Acute Myeloid Leukemia
  • Anti-CD33/CLL1 CAR-NK Cells
  • Wuxi, Jiangsu, China
    Wuxi People's Hospital
Jan 18, 2022

Acute Myeloid Leukemia Trial in Beijing, Tianjin (LCAR-AMDR Cells Product)

Recruiting
  • Acute Myeloid Leukemia
  • LCAR-AMDR Cells Product
  • Beijing, Beijing, China
  • +1 more
Jan 28, 2023

Acute Myeloid Leukemia Trial in Beijing (Dual CD33/CLL1 CAR T)

Recruiting
  • Acute Myeloid Leukemia
  • Dual CD33/CLL1 CAR T
  • Beijing, Beijing, China
    Beijing Boren Hospital
Feb 16, 2022

Leukemia, Myeloid, Acute Trial in Chongqing (Fludarabine, Cytoxan, Dual CD33-CLL1 CAR-T cells)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • Chongqing, Chongqing, China
    Department of Hematology, Xinqiao Hospital
Aug 20, 2021

Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance

Not yet recruiting
  • Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)
    • (no location specified)
    Dec 16, 2022

    AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)

    Not yet recruiting
    • AML, Adult
    • Minimal Residual Disease
    • CD33/CLL1 dual CAR-NK cell
    • +5 more
    • Tianjin, China
      Institute of Hematology & Blood Diseases Hospital
    Aug 4, 2023

    Acute Myeloid Leukemia Trial in Suzhou (anti-CLL1 CART)

    Recruiting
    • Acute Myeloid Leukemia
    • anti-CLL1 CART
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    May 10, 2021

    Acute Myeloid Leukemia Trial in Beijing, Shenzhen, Haikou (CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells)

    Recruiting
    • Acute Myeloid Leukemia
    • CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
    • Beijing, Beijing, China
    • +2 more
    Aug 8, 2023

    Hematologic Malignancy, Acute Myeloid Leukemia, MDS Trial in Chengdu, Shenzhen (CLL1-CD33 cCAR T cells)

    Recruiting
    • Hematologic Malignancy
    • +4 more
    • CLL1-CD33 cCAR T cells
    • Chengdu, China
    • +1 more
    May 17, 2021

    CLL, SLL Trial in Boston (Ofatumumab, High-Dose Methylprednisolone, Alemtuzumab)

    Terminated
    Has Results
    • CLL
    • SLL
    • Boston, Massachusetts
    • +1 more
    Jan 30, 2023

    Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma Trial (Nemtabrutinib, Venetoclax,

    Not yet recruiting
    • Leukemia, Lymphocytic, Chronic, B-Cell
    • +5 more
    • (no location specified)
    Jul 21, 2023

    Acute Myeloid Leukemia Trial in United States (Cyclophosphamide, Fludarabine, KITE-222)

    Recruiting
    • Acute Myeloid Leukemia
    • Stanford, California
    • +6 more
    Aug 10, 2022

    Chronic Lymphocytic Leukemia, CLL, Relapsed CLL Trial (Dose combination 1-1, dose combination 1-2, Dose combination 1-3)

    Withdrawn
    • Chronic Lymphocytic Leukemia
    • +8 more
    • Dose combination 1-1
    • +5 more
    • (no location specified)
    Nov 1, 2021

    Chronic Lymphocytic Leukemia Trial in Lebanon (BNC105P, Ibrutinib)

    Completed
    • Chronic Lymphocytic Leukemia
    • BNC105P
    • Ibrutinib
    • Lebanon, New Hampshire
      Dartmouth-Hitchcock Medical Center
    Jan 3, 2023

    Chronic Lymphocytic Leukemia Trial in Poland, United Kingdom (Ceralasertib, Acalabrutinib)

    Active, not recruiting
    • Chronic Lymphocytic Leukemia
    • Kraków, Poland
    • +10 more
    Dec 2, 2022

    NHL, Leukemia Trial in Australia (ETH-155008)

    Recruiting
    • NHL
    • Leukemia
    • Adelaide, South Australia, Australia
    • +4 more
    Jun 8, 2022

    Chronic Lymphocytic Leukemia, CLL, SLL Trial in United States (TP-0903, TP-0903 and ibrutinib combination therapy)

    Terminated
    Has Results
    • Chronic Lymphocytic Leukemia
    • +3 more
    • TP-0903
    • TP-0903 and ibrutinib combination therapy
    • Phoenix, Arizona
    • +5 more
    Apr 4, 2022